Cargando…

Stringent Response in Mycobacteria: From Biology to Therapeutic Potential

Mycobacterium tuberculosis is a human pathogen that can thrive inside the host immune cells for several years and cause tuberculosis. This is due to the propensity of M. tuberculosis to synthesize a sturdy cell wall, shift metabolism and growth, secrete virulence factors to manipulate host immunity,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Kuldeepkumar Ramnaresh, Arora, Gunjan, Mattoo, Abid, Sajid, Andaleeb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622095/
https://www.ncbi.nlm.nih.gov/pubmed/34832573
http://dx.doi.org/10.3390/pathogens10111417
_version_ 1784605613759660032
author Gupta, Kuldeepkumar Ramnaresh
Arora, Gunjan
Mattoo, Abid
Sajid, Andaleeb
author_facet Gupta, Kuldeepkumar Ramnaresh
Arora, Gunjan
Mattoo, Abid
Sajid, Andaleeb
author_sort Gupta, Kuldeepkumar Ramnaresh
collection PubMed
description Mycobacterium tuberculosis is a human pathogen that can thrive inside the host immune cells for several years and cause tuberculosis. This is due to the propensity of M. tuberculosis to synthesize a sturdy cell wall, shift metabolism and growth, secrete virulence factors to manipulate host immunity, and exhibit stringent response. These attributes help M. tuberculosis to manage the host response, and successfully establish and maintain an infection even under nutrient-deprived stress conditions for years. In this review, we will discuss the importance of mycobacterial stringent response under different stress conditions. The stringent response is mediated through small signaling molecules called alarmones “(pp)pGpp”. The synthesis and degradation of these alarmones in mycobacteria are mediated by Rel protein, which is both (p)ppGpp synthetase and hydrolase. Rel is important for all central dogma processes—DNA replication, transcription, and translation—in addition to regulating virulence, drug resistance, and biofilm formation. Rel also plays an important role in the latent infection of M. tuberculosis. Here, we have discussed the literature on alarmones and Rel proteins in mycobacteria and highlight that (p)ppGpp-analogs and Rel inhibitors could be designed and used as antimycobacterial compounds against M. tuberculosis and non-tuberculous mycobacterial infections.
format Online
Article
Text
id pubmed-8622095
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86220952021-11-27 Stringent Response in Mycobacteria: From Biology to Therapeutic Potential Gupta, Kuldeepkumar Ramnaresh Arora, Gunjan Mattoo, Abid Sajid, Andaleeb Pathogens Review Mycobacterium tuberculosis is a human pathogen that can thrive inside the host immune cells for several years and cause tuberculosis. This is due to the propensity of M. tuberculosis to synthesize a sturdy cell wall, shift metabolism and growth, secrete virulence factors to manipulate host immunity, and exhibit stringent response. These attributes help M. tuberculosis to manage the host response, and successfully establish and maintain an infection even under nutrient-deprived stress conditions for years. In this review, we will discuss the importance of mycobacterial stringent response under different stress conditions. The stringent response is mediated through small signaling molecules called alarmones “(pp)pGpp”. The synthesis and degradation of these alarmones in mycobacteria are mediated by Rel protein, which is both (p)ppGpp synthetase and hydrolase. Rel is important for all central dogma processes—DNA replication, transcription, and translation—in addition to regulating virulence, drug resistance, and biofilm formation. Rel also plays an important role in the latent infection of M. tuberculosis. Here, we have discussed the literature on alarmones and Rel proteins in mycobacteria and highlight that (p)ppGpp-analogs and Rel inhibitors could be designed and used as antimycobacterial compounds against M. tuberculosis and non-tuberculous mycobacterial infections. MDPI 2021-11-01 /pmc/articles/PMC8622095/ /pubmed/34832573 http://dx.doi.org/10.3390/pathogens10111417 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gupta, Kuldeepkumar Ramnaresh
Arora, Gunjan
Mattoo, Abid
Sajid, Andaleeb
Stringent Response in Mycobacteria: From Biology to Therapeutic Potential
title Stringent Response in Mycobacteria: From Biology to Therapeutic Potential
title_full Stringent Response in Mycobacteria: From Biology to Therapeutic Potential
title_fullStr Stringent Response in Mycobacteria: From Biology to Therapeutic Potential
title_full_unstemmed Stringent Response in Mycobacteria: From Biology to Therapeutic Potential
title_short Stringent Response in Mycobacteria: From Biology to Therapeutic Potential
title_sort stringent response in mycobacteria: from biology to therapeutic potential
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622095/
https://www.ncbi.nlm.nih.gov/pubmed/34832573
http://dx.doi.org/10.3390/pathogens10111417
work_keys_str_mv AT guptakuldeepkumarramnaresh stringentresponseinmycobacteriafrombiologytotherapeuticpotential
AT aroragunjan stringentresponseinmycobacteriafrombiologytotherapeuticpotential
AT mattooabid stringentresponseinmycobacteriafrombiologytotherapeuticpotential
AT sajidandaleeb stringentresponseinmycobacteriafrombiologytotherapeuticpotential